Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-302-5018 in Idiopathic Overactive Bladder
NCT03109379Phase 1Completed
- Sponsor
- TARIS Biomedical
- Start
- Apr 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trospium in overactive bladder (OAB) and urinary incontinence (UI) (2 arms), sponsored by TARIS Biomedical. Primary endpoint: Safety of TAR-302-5018 assessed based on reported Adverse Events. Started Apr 2017; status: completed.
02
Drugs
trospium
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT03109379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03109379.